

## A US Multi-center, Prospective, Non-interventional, Long-term, Effectiveness and Safety Study of Patients Treated with SKYTROFA (lonapegsomatropin) (SkybriGHt)

**Status:** Recruiting

### Eligibility Criteria

**Sex:** Male or Female

**Age Group:** Up to 18 years old

This study is NOT accepting healthy volunteers

**Inclusion Criteria:**

- 1 to 18 years old - on treatment with SKYTROFA (lonapegsomatropin)

---

**Exclusion Criteria:**

- participating in any interventional clinical study

### Conditions & Interventions

**Conditions:**

Rare Diseases

**Keywords:**

growth hormone, growth hormone deficiency

### More Information

**Description:** Skytrofa is approved in the U.S. for sale and use in children with growth hormone deficiency (GHD). This study is being done to find out how safe and useful Skytrofa is for long-term treatment. A child's care will follow the normal treatment practices at the clinic. There is no new treatment or medicine involved and no additional visits will be performed.

**Study Contact:** Brad Miller - [mille685@umn.edu](mailto:mille685@umn.edu)

**Principal Investigator:** Brad Miller, MD, PhD

**IRB**

**Number:** SITE00002031

---

Thank you for choosing StudyFinder. Please visit <http://studyfinder.umn.edu> to find a Study which is right for you and contact [sfinder@umn.edu](mailto:sfinder@umn.edu) if you have questions or need assistance.